Phase 2 Retinal Vein Occlusion and Diabetic Macular Oedema Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are between 40 and 69 years old (inclusive).
- You are male or female and have been diagnosed with mild or moderate diabetic macular edema (a diabetes-related eye condition causing swelling), non-proliferative diabetic retinopathy, or proliferative diabetic retinopathy and are scheduled for a medically recommended eye surgery called vitrectomy.
- You are willing and able to sign a consent form agreeing to take part in the study.
- You do not have serious eye complications such as severe short-sightedness (stronger than -6 diopters), clouding of the eye, or a detached retina.
- You have not had previous eye surgeries, laser treatment on your retina, or injections into the eye within the last 6 months.
- Your blood prolactin level (a hormone measured by a blood test) is at or below 20 ng/ml.
- Your kidneys are working normally or with only mild reduction in function (confirm with trial site for your specific group).
- You do not have any medical reason that would prevent you from taking a medication called levosulpiride — for example, you do not have Parkinson's disease, epilepsy, breast cancer, alcoholism, or low potassium levels.
- You do not have any condition or take any medication known to raise prolactin levels, such as an underactive thyroid, liver problems, a prolactin-producing tumor, or certain psychiatric or stomach medications.
Who may not be able to join:
- You do not meet the requirements listed above.
- You experience side effects from the study medication that you cannot tolerate.
- You are unable or unwilling to take the study medication as instructed.
- You are unable to attend the required hospital appointments.
- Important information about your health outcomes cannot be collected.
- You change your mind and no longer wish to continue taking the study medication.
- You move to a different state or country during the study.
- You choose to withdraw your consent to participate at any time.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Carmen Clapp, Ph.D., Universidad Nacional Autonoma de Mexico (UNAM)
Phone: 52442 2381028
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Visual acuity; Retinal thickness; Retinal hard exudates and hemorrhages; Retinal microaneurisms, leakage area, cotton-wool spots, venous beading, microvascular and vascular abnormalities; Prolactin serum levels; Prolactin vitreous levels; Vasoinhibin vitreous levels
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.